Skip to main content
Premium Trial:

Request an Annual Quote

FDA To Use Rosetta's Syllego to Analyze Genotyping Data in VXDS Program

NEW YORK (Genome Web News) - Rosetta Biosoftware said today that the US Food and Drug Administration will use its Syllego software to manage and analyze genotyping data used from genome-wide association studies that are submitted under the FDA’s Voluntary eXploratory Data Submission program.
"There are a growing number of genome-wide association study data submissions to the FDA through VXDS," said Weida Tong, director of the Center for Toxicoinformatics at the FDA’s National Center for Toxicological Research.
Tong added that Syllego “allows us to effectively manage genotyping data submissions and also carry out analyses to understand why the sponsor might have used a particular method to arrive at a specific outcome.”
The NCTR will also “explore the possibility” of integrating Syllego system with its own ArrayTrack software.
The FDA’s Center for Drug Evaluation and Research is already using the company’s Rosetta Resolver software for gene expression data management and analysis under the VXDS program.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.